Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor from Asceneuron, exclusively to treat Progressive Supranuclear Palsy (PSP)

Feb 22, 2023

Posted by FERRER INTERNACIONAL

Press Release

Feb 22, 2023

Posted by ONTOFORCE, Inc.

Babson Students Work to Improve Healthcare in Rwanda

Feb 21, 2023

Posted by Babson College

MassBio New Member Announcement—MERIT CRO

Feb 20, 2023

Posted by MERIT CRO

New Member Announcement—RockStep Solutions

Feb 16, 2023

Implementing Decentralized Clinical Trials: Strategic Design Vs. “Retrofitting”

Feb 16, 2023

Clinical Registries and RWD: Where We Are in the Integration Process?

Feb 16, 2023

Speeding Acquisition Integration with a Pathfinder

Feb 16, 2023

Syneos Health Dealmakers’ Intentions Survey Sees “Optimism” for M&A Licensing Deals for 2023

Feb 16, 2023